Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Predicting Survival in Patients with Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison with ESC/ERS-Based Risk Assessment Strategies.

Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE, McGoon MD, Pasta DJ, Selej M, Burger CD, Frantz RP.

Chest. 2019 Feb 14. pii: S0012-3692(19)30152-7. doi: 10.1016/j.chest.2019.02.004. [Epub ahead of print]

2.

Harvest of Endothelial Cells from the Balloon Tips of Swan-Ganz Catheters after Right Heart Catheterization.

Passineau MJ, Gallo PH, Williams G, Perez R, Benza RL.

J Vis Exp. 2019 Jan 23;(143). doi: 10.3791/58353.

PMID:
30735186
3.

Risk Assessment in Patients with a Left Ventricular Assist Device Across INTERMACS Profiles Using Bayesian Analysis.

Kanwar MK, Lohmueller LC, Teuteberg J, Kormos RL, Rogers JG, Benza RL, Lindenfeld J, McIlvennan C, Bailey SH, Murali S, Antaki JF.

ASAIO J. 2019 Jan 24. doi: 10.1097/MAT.0000000000000910. [Epub ahead of print]

PMID:
30688695
4.

Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension.

Hoeper MM, Benza RL, Corris P, de Perrot M, Fadel E, Keogh AM, Kühn C, Savale L, Klepetko W.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801906. doi: 10.1183/13993003.01906-2018. Print 2019 Jan.

5.

Response.

Frantz RP, Zhao C, Farber HW, Badesch DB, Elliott CG, Frost AE, McGoon MD, Mink DR, Selej M, Benza RL.

Chest. 2018 Nov;154(5):1262-1264. doi: 10.1016/j.chest.2018.07.033. No abstract available.

PMID:
30409362
6.

Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.

Frost A, Janmohamed M, Fritz JS, McConnell JW, Poch D, Fortin TA, Miller CE, Chin KM, Fisher M, Eggert M, McEvoy C, Benza RL, Farber HW, Kim NH, Pfister T, Shiraga Y, McLaughlin V.

J Heart Lung Transplant. 2019 Jan;38(1):43-50. doi: 10.1016/j.healun.2018.09.003. Epub 2018 Sep 12.

7.

Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension?

Khan MS, Usman MS, Siddiqi TJ, Khan SU, Murad MH, Mookadam F, Figueredo VM, Krasuski RA, Benza RL, Rich JD.

Circ Cardiovasc Qual Outcomes. 2018 Sep;11(9):e004757. doi: 10.1161/CIRCOUTCOMES.118.004757.

PMID:
30354550
8.

Bloodstream Infections in Continuous Flow Left Ventricular Assist Device Recipients: Diagnostic and Clinical Implications.

Kyvernitakis A, Pappas O, Farmakiotis D, Horn ET, Benza RL, Bailey SH, Agarwal R.

ASAIO J. 2018 Sep 17. doi: 10.1097/MAT.0000000000000881. [Epub ahead of print]

PMID:
30234503
9.

A Novel Compound, "FA-1" Isolated from Prunus mume, Protects Human Bronchial Epithelial Cells and Keratinocytes from Cigarette Smoke Extract-Induced Damage.

Jang AJ, Lee JH, Yotsu-Yamashita M, Park J, Kye S, Benza RL, Passineau MJ, Jeon YJ, Nyunoya T.

Sci Rep. 2018 Jul 31;8(1):11504. doi: 10.1038/s41598-018-29701-2.

10.

Association between cytokines and functional, hemodynamic parameters, and clinical outcomes in pulmonary arterial hypertension.

Joshi AA, Davey R, Rao Y, Shen K, Benza RL, Raina A.

Pulm Circ. 2018 Jul-Sep;8(3):2045894018794051. doi: 10.1177/2045894018794051. Epub 2018 Jul 23.

11.

Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL.

Farber HW, Badesch DB, Benza RL, Elliott CG, Frantz RP, McGoon MD, Selej M, Zhao C, Frost AE.

J Heart Lung Transplant. 2018 Aug;37(8):948-955. doi: 10.1016/j.healun.2018.03.010. Epub 2018 Mar 17.

PMID:
29653800
12.

REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat.

Benza RL, Farber HW, Frost A, Grünig E, Hoeper MM, Busse D, Meier C, Nikkho S, Ghofrani HA.

J Heart Lung Transplant. 2018 Jul;37(7):836-843. doi: 10.1016/j.healun.2018.02.015. Epub 2018 Mar 1.

13.

Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report.

Elinoff JM, Agarwal R, Barnett CF, Benza RL, Cuttica MJ, Gharib AM, Gray MP, Hassoun PM, Hemnes AR, Humbert M, Kolb TM, Lahm T, Leopold JA, Mathai SC, McLaughlin VV, Preston IR, Rosenzweig EB, Shlobin OA, Steen VD, Zamanian RT, Solomon MA.

Am J Respir Crit Care Med. 2018 Jul 15;198(2):166-174. doi: 10.1164/rccm.201710-2093PP. No abstract available.

PMID:
29425462
14.

Risk Assessment Tools in Pulmonary Arterial Hypertension. Prognosis for Prospective Trials?

Farber HW, Benza RL.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):843-845. doi: 10.1164/rccm.201801-0042ED. No abstract available.

PMID:
29373796
15.

Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry.

Frantz RP, Farber HW, Badesch DB, Elliott CG, Frost AE, McGoon MD, Zhao C, Mink DR, Selej M, Benza RL.

Chest. 2018 Jul;154(1):126-135. doi: 10.1016/j.chest.2018.01.009. Epub 2018 Jan 31.

PMID:
29355551
16.

The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension: A meta-analysis.

Vizza CD, Badagliacca R, Messick CR, Rao Y, Nelsen AC, Benza RL.

Int J Cardiol. 2018 Mar 1;254:299-301. doi: 10.1016/j.ijcard.2017.12.016. Epub 2017 Dec 14.

17.

REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival.

Benza RL, Farber HW, Frost A, Ghofrani HA, Gómez-Sánchez MA, Langleben D, Rosenkranz S, Busse D, Meier C, Nikkho S, Hoeper MM.

J Heart Lung Transplant. 2018 Apr;37(4):513-519. doi: 10.1016/j.healun.2017.11.006. Epub 2017 Nov 11.

18.

Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes.

Burger CD, Ghandour M, Padmanabhan Menon D, Helmi H, Benza RL.

Clinicoecon Outcomes Res. 2017 Nov 24;9:731-739. doi: 10.2147/CEOR.S119117. eCollection 2017. Review.

19.

Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis.

Chakinala MM, Coyne DW, Benza RL, Frost AE, McGoon MD, Hartline BK, Frantz RP, Selej M, Zhao C, Mink DR, Farber HW.

J Heart Lung Transplant. 2018 Jun;37(6):696-705. doi: 10.1016/j.healun.2017.10.028. Epub 2017 Nov 6.

PMID:
29174533
20.

Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study.

Benza RL, Raina A, Gupta H, Murali S, Burden A, Zastrow MS, Park MH, Simon MA.

Pulm Circ. 2018 Jan-Mar;8(1):2045893217741480. doi: 10.1177/2045893217741480. Epub 2017 Oct 24.

21.

Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension.

Badagliacca R, Raina A, Ghio S, D'Alto M, Confalonieri M, Correale M, Corda M, Paciocco G, Lombardi C, Mulè M, Poscia R, Scelsi L, Argiento P, Sciomer S, Benza RL, Vizza CD.

J Heart Lung Transplant. 2018 Mar;37(3):365-375. doi: 10.1016/j.healun.2017.08.009. Epub 2017 Aug 26.

PMID:
28912026
22.

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.

Hoeper MM, Simonneau G, Corris PA, Ghofrani HA, Klinger JR, Langleben D, Naeije R, Jansa P, Rosenkranz S, Scelsi L, Grünig E, Vizza CD, Chang M, Colorado P, Meier C, Busse D, Benza RL.

Eur Respir J. 2017 Sep 9;50(3). pii: 1602425. doi: 10.1183/13993003.02425-2016. Print 2017 Sep.

23.

Assessing risk in pulmonary arterial hypertension: what we know, what we don't.

Benza RL, Farber HW, Selej M, Gomberg-Maitland M.

Eur Respir J. 2017 Aug 3;50(2). pii: 1701353. doi: 10.1183/13993003.01353-2017. Print 2017 Aug. No abstract available.

24.

Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series.

Raina A, Benza RL, Farber HW.

Pulm Circ. 2017 Jul-Sep;7(3):741-746. doi: 10.1177/2045893217721694. Epub 2017 Aug 3.

25.

Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension.

Davey R, Benza RL, Murali S, Raina A.

Pulm Circ. 2017 Apr-Jun;7(2):539-542. doi: 10.1177/2045893217708566. Epub 2017 May 12.

26.

MicroCT analysis of vascular morphometry: a comparison of right lung lobes in the SUGEN/hypoxic rat model of pulmonary arterial hypertension.

Faight EM, Verdelis K, Zourelias L, Chong R, Benza RL, Shields KJ.

Pulm Circ. 2017 Apr-Jun;7(2):522-530. doi: 10.1177/2045893217709001. Epub 2017 May 12.

27.

In vivo Endocrine Secretion of Prostacyclin Following Expression of a Cyclooxygenase-1/Prostacyclin Fusion Protein in the Salivary Glands of Rats Via Nonviral Gene Therapy.

Wang Z, Benza RL, Zourelias L, Sanguino A, Geguchadze R, Shields KJ, Wu C, Highland KB, Passineau MJ.

Hum Gene Ther. 2017 Aug;28(8):681-689. doi: 10.1089/hum.2017.040.

28.

Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.

Newman JH, Rich S, Abman SH, Alexander JH, Barnard J, Beck GJ, Benza RL, Bull TM, Chan SY, Chun HJ, Doogan D, Dupuis J, Erzurum SC, Frantz RP, Geraci M, Gillies H, Gladwin M, Gray MP, Hemnes AR, Herbst RS, Hernandez AF, Hill NS, Horn EM, Hunter K, Jing ZC, Johns R, Kaul S, Kawut SM, Lahm T, Leopold JA, Lewis GD, Mathai SC, McLaughlin VV, Michelakis ED, Nathan SD, Nichols W, Page G, Rabinovitch M, Rich J, Rischard F, Rounds S, Shah SJ, Tapson VF, Lowy N, Stockbridge N, Weinmann G, Xiao L.

Am J Respir Crit Care Med. 2017 Jun 15;195(12):1661-1670. doi: 10.1164/rccm.201701-0150WS.

29.
30.

Three-dimensional micro computed tomography analysis of the lung vasculature and differential adipose proteomics in the Sugen/hypoxia rat model of pulmonary arterial hypertension.

Shields KJ, Verdelis K, Passineau MJ, Faight EM, Zourelias L, Wu C, Chong R, Benza RL.

Pulm Circ. 2016 Dec;6(4):586-596. doi: 10.1086/688931.

31.

In situ expression of Bcl-2 in pulmonary artery endothelial cells associates with pulmonary arterial hypertension relative to heart failure with preserved ejection fraction.

Benza RL, Williams G, Wu C, Shields KJ, Raina A, Murali S, Passineau MJ.

Pulm Circ. 2016 Dec;6(4):551-556. doi: 10.1086/688774.

32.

Does Late Gadolinium Enhancement still have Value? Right Ventricular Internal Mechanical Work, Ea/Emax and Late Gadolinium Enhancement as Prognostic Markers in Patients with Advanced Pulmonary Hypertension via Cardiac MRI.

Abouelnour AE, Doyle M, Thompson DV, Yamrozik J, Williams RB, Shah MB, Soma SK, Murali S, Benza RL, Biederman RW.

Cardiol Res Cardiovasc Med. 2017;2017(1). pii: CRCM-111. Epub 2017 Jan 11.

33.

Significance of Residual Mitral Regurgitation After Continuous Flow Left Ventricular Assist Device Implantation.

Kassis H, Cherukuri K, Agarwal R, Kanwar M, Elapavaluru S, Sokos GG, Moraca RJ, Bailey SH, Murali S, Benza RL, Raina A.

JACC Heart Fail. 2017 Feb;5(2):81-88. doi: 10.1016/j.jchf.2016.09.014. Epub 2016 Dec 21.

34.

Low Accuracy of the HeartMate Risk Score for Predicting Mortality Using the INTERMACS Registry Data.

Kanwar MK, Lohmueller LC, Kormos RL, Loghmanpour NA, Benza RL, Mentz RJ, Bailey SH, Murali S, Antaki JF.

ASAIO J. 2017 May/Jun;63(3):251-256. doi: 10.1097/MAT.0000000000000494.

35.

Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.

Hoeper MM, Klinger JR, Benza RL, Simonneau G, Langleben D, Naeije R, Corris PA.

Respir Med. 2017 Jan;122 Suppl 1:S18-S22. doi: 10.1016/j.rmed.2016.11.001. Epub 2016 Nov 5.

36.

TLR4 regulates pulmonary vascular homeostasis and remodeling via redox signaling.

Ma L, Ambalavanan N, Liu H, Sun Y, Jhala N, Bradley WE, Dell'Italia LJ, Michalek S, Wu H, Steele C, Benza RL, Chen Y.

Front Biosci (Landmark Ed). 2016 Jan 1;21:397-409.

37.

Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension.

Benza RL, Gomberg-Maitland M, Demarco T, Frost AE, Torbicki A, Langleben D, Pulido T, Correa-Jaque P, Passineau MJ, Wiener HW, Tamari M, Hirota T, Kubo M, Tiwari HK.

Am J Respir Crit Care Med. 2015 Dec 1;192(11):1345-54. doi: 10.1164/rccm.201501-0196OC.

38.

Reply: Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration.

Hill NS, Badesch D, Benza RL, D'Eletto TA, Farber HW, Gomberg-Maitland M, Hassoun PM, Preston I.

Ann Am Thorac Soc. 2015 Jun;12(6):960. doi: 10.1513/AnnalsATS.201505-263LE. No abstract available.

PMID:
26075562
39.

Five-Year outcomes of patients enrolled in the REVEAL Registry.

Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, Romero AJ, Benton WW, Elliott CG, McGoon MD, Benza RL.

Chest. 2015 Oct;148(4):1043-54. doi: 10.1378/chest.15-0300.

40.

Validation of two predictive models for survival in pulmonary arterial hypertension.

Sitbon O, Benza RL, Badesch DB, Barst RJ, Elliott CG, Gressin V, Lemarié JC, Miller DP, Muros-Le Rouzic E, Simonneau G, Frost AE, Farber HW, Humbert M, McGoon MD.

Eur Respir J. 2015 Jul;46(1):152-64. doi: 10.1183/09031936.00004414. Epub 2015 Apr 2.

41.

Limitations of right heart catheterization in the diagnosis and risk stratification of patients with pulmonary hypertension related to left heart disease: insights from a wireless pulmonary artery pressure monitoring system.

Raina A, Abraham WT, Adamson PB, Bauman J, Benza RL.

J Heart Lung Transplant. 2015 Mar;34(3):438-47. doi: 10.1016/j.healun.2015.01.983. Epub 2015 Feb 7.

PMID:
25813770
42.

A new Bayesian network-based risk stratification model for prediction of short-term and long-term LVAD mortality.

Loghmanpour NA, Kanwar MK, Druzdzel MJ, Benza RL, Murali S, Antaki JF.

ASAIO J. 2015 May-Jun;61(3):313-23. doi: 10.1097/MAT.0000000000000209.

43.

[Pulmonary arterial hypertension: epidemiology and registries].

McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, Pepke-Zaba J, Pulido T, Rich S, Rosenkranz S, Suissa S, Humbert M.

Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:67-77. Turkish.

44.

Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.

Hill NS, Badesch D, Benza RL, D'Eletto TA, Farber HW, Gomberg-Maitland M, Hassoun PM, Preston I.

Ann Am Thorac Soc. 2015 Feb;12(2):269-73. doi: 10.1513/AnnalsATS.201501-020AS.

PMID:
25590376
45.

Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension.

Damico R, Kolb TM, Valera L, Wang L, Housten T, Tedford RJ, Kass DA, Rafaels N, Gao L, Barnes KC, Benza RL, Rand JL, Hamid R, Loyd JE, Robbins IM, Hemnes AR, Chung WK, Austin ED, Drummond MB, Mathai SC, Hassoun PM.

Am J Respir Crit Care Med. 2015 Jan 15;191(2):208-18. doi: 10.1164/rccm.201409-1742OC.

46.

Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis.

Benza RL, Miller DP, Foreman AJ, Frost AE, Badesch DB, Benton WW, McGoon MD.

J Heart Lung Transplant. 2015 Mar;34(3):356-61. doi: 10.1016/j.healun.2014.09.016. Epub 2014 Sep 28.

47.

Management of pulmonary hypertension due to heart failure with preserved ejection fraction.

Kanwar M, Tedford RJ, Agarwal R, Clarke MM, Walter C, Sokos G, Murali S, Benza RL.

Curr Hypertens Rep. 2014 Dec;16(12):501. doi: 10.1007/s11906-014-0501-5. Review.

PMID:
25320018
48.

Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance.

Farber HW, Miller DP, McGoon MD, Frost AE, Benton WW, Benza RL.

J Heart Lung Transplant. 2015 Mar;34(3):362-8. doi: 10.1016/j.healun.2014.08.020. Epub 2014 Aug 28.

49.

Successful treatment of acute left ventricular assist device thrombosis and cardiogenic shock with intraventricular thrombolysis and a tandem heart.

Agarwal R, Raina A, Lasorda DM, Moraca RJ, Bailey SH, Kanwar M, Sokos G, Murali S, Benza RL.

ASAIO J. 2015 Jan-Feb;61(1):98-101. doi: 10.1097/MAT.0000000000000149.

PMID:
25248042
50.

Pulmonary hypertension related to left heart disease: insight from a wireless implantable hemodynamic monitor.

Benza RL, Raina A, Abraham WT, Adamson PB, Lindenfeld J, Miller AB, Bourge RC, Bauman J, Yadav J.

J Heart Lung Transplant. 2015 Mar;34(3):329-37. doi: 10.1016/j.healun.2014.04.014. Epub 2014 May 10.

PMID:
24999252

Supplemental Content

Loading ...
Support Center